Rising Drug Costs: A Prescription for Action

  • November 15, 2017
  • 1:00 PM – 2:00 PM ET
  • Online
about

The national conversation over rising drug prices has grown acrimonious in the last year. The health care industry’s shift to value-based payment reforms and the increased financial pressures on consumers urgently requires a fresh approach to managing prescription drug costs. Last summer’s EpiPen controversy and this year’s opioid crisis have put a further spotlight on these issues. The primary focus of this webinar is to raise awareness on the importance of Rx drug price transparency and the major trends key stakeholders need to address in 2018 and beyond. Most importantly, industry experts will provide prescriptive actions that can positively impact health plan members and business costs.

This session will explore key data findings and megatrends of the prescription drug market, and what to expect in 2018 and beyond. The industry experts will discuss specific ways to build actionable retention and engagement strategies for Rx plan members. They will demonstrate how plans, providers and PBMs can better prioritize the member experience in their go-forward initiatives and realize significant cost savings.

In this session, experts will explore the most critical Rx issues facing health insurers and pharmacy benefit managers, and unveil:

  • 5 trends and key legislative efforts that are shifting the conversation around pharmaceutical cost management, including generic and specialty drug options
  • The changing dialogue between members and their physicians around prescription drug management
  • How payers and PBMs can make the process of prescription drug selection easier for members, and provide more effective ways to control out-of-pocket costs

Who should attend:

  • Health Plans, Provider-Sponsored Health Plans, PBMs, and associated Transparency Companies
  • Will appeal to 3 primary roles and personas at those companies (Clinical, Marketing, and Finance)

Speakers:


Janie Kim
Director of Clinical Services, Licensed PharmD

Janie Kim is a pharmacist and the Director of Clinical Services at Connecture. Janie received her PharmD in 1998 and completed her Pharmacy Practice Residency the following year. Her career spans multiple practice settings including, retail pharmacy, hospital pharmacy, and managed care. She has worked extensively with patients and physicians as well working for large PBMs and leading teams that developed Medication Management and Disease Management programs. In her current role, she is responsible for leading the team that develops and maintains Connecture’s Therapeutic Alternatives Database.


Dave Sockel
EVP, Corporate and Product Strategy at Connecture

David has more than two decades of experience in sales, operations and strategy with Fortune 500 companies and top-tier consulting firms in the healthcare industry. A co-founder of Connecture, he brings valuable insight into the intricacies of the health insurance industry to the company. David also has a proven track record of success developing winning approaches that address the emerging trends poised to transform the distribution of health coverage – foresight that builds on his ability to simultaneously identify new ways in which technology can be used to grow revenue, increase efficiency and maximize the return on investment of healthcare dollars. Prior to Connecture, David was senior manager at Ernst & Young’s Health Care Strategy Group, where he focused on the health insurance sector.


Rebecca Molesworth
Senior Director of Product of Management at Connecture

Rebecca Molesworth is the Senior Director of Product of Management at Connecture. Rebecca has an extensive background in wellness, disease management, healthcare data analytics, and population health analytics, having previously worked for organizations such as Truven Health Analytics, WebMD and Matria Healthcare. At Connecture, Rebecca is responsible for identifying market trends and evolving policy landscape, packaging and positioning of emerging product solutions, guiding the product development organization with definition and prioritization of product initiatives, balancing multiple customer needs as well as evaluating potential partnerships / M&A targets to support strategic goals.